| Literature DB >> 16908411 |
Krisztina Monory1, Federico Massa, Michaela Egertová, Matthias Eder, Heike Blaudzun, Ruth Westenbroek, Wolfgang Kelsch, Wolfgang Jacob, Rudolf Marsch, Marc Ekker, Jason Long, John L Rubenstein, Sandra Goebbels, Klaus-Armin Nave, Matthew During, Matthias Klugmann, Barbara Wölfel, Hans-Ulrich Dodt, Walter Zieglgänsberger, Carsten T Wotjak, Ken Mackie, Maurice R Elphick, Giovanni Marsicano, Beat Lutz.
Abstract
Balanced control of neuronal activity is central in maintaining function and viability of neuronal circuits. The endocannabinoid system tightly controls neuronal excitability. Here, we show that endocannabinoids directly target hippocampal glutamatergic neurons to provide protection against acute epileptiform seizures in mice. Functional CB1 cannabinoid receptors are present on glutamatergic terminals of the hippocampal formation, colocalizing with vesicular glutamate transporter 1 (VGluT1). Conditional deletion of the CB1 gene either in cortical glutamatergic neurons or in forebrain GABAergic neurons, as well as virally induced deletion of the CB1 gene in the hippocampus, demonstrate that the presence of CB1 receptors in glutamatergic hippocampal neurons is both necessary and sufficient to provide substantial endogenous protection against kainic acid (KA)-induced seizures. The direct endocannabinoid-mediated control of hippocampal glutamatergic neurotransmission may constitute a promising therapeutic target for the treatment of disorders associated with excessive excitatory neuronal activity.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16908411 PMCID: PMC1769341 DOI: 10.1016/j.neuron.2006.07.006
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173